FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

82 letters match. Newest first.

  1. Guangzhou Jiugong Research And Development Biotechnology Co., Ltd.

    Guangzhou Jiugong, an OTC drug maker, used a color additive FDA cancelled in 1976 and fell short of CGMP.

    High risk
  2. Olympus Medical Systems Corporation

    FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.

    High risk
  3. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  4. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk
  5. Middlefield Original Cheese Cooperative

    FDA warns Middlefield Original Cheese Cooperative about Listeria and insanitary conditions in its ready-to-eat cheese.

    High risk
  6. Union Trade Inc.

    FDA warns Union Trade Inc. that it lacked required foreign supplier verification for imported radish, peanuts, mushrooms, and fruit.

    High risk
  7. K.C. Pharmaceuticals, Inc.

    FDA cited K.C. Pharmaceuticals of Pomona, CA, for sterile-drug manufacturing failures, including aseptic practice problems and failed media fills.

    High risk
  8. Woodbine Products Company Inc.

    Inspection found Woodbine Products, an Ohio OTC drug maker, failed to test incoming ingredients like glycerin and propylene glycol for identity.

    High risk
  9. Umendra Life Sciences Private Limited

    Umendra Life Sciences, an Indian maker of OTC talc-containing drugs, failed CGMP on talc testing and asbestos control, FDA says.

    High risk
  10. Shantou Qiwei Industry Co., LTD

    FDA warns Shantou Qiwei, a Chinese OTC drug maker, that it never tested talc for asbestos, making its products adulterated.

    High risk
  11. Zydus Lifesciences Limited

    FDA warns Zydus Lifesciences over untested asbestos in talc used in its prescription drugs and altered lab data at its Himachal Pradesh plant.

    High risk
  12. GC America, Inc.

    FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.

    High risk
  13. Lexia LLC

    FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.

    High risk
  14. Pure Indulgence Aesthetics

    Pure Indulgence Aesthetics, a medical spa, was cited for buying Botox from unauthorized sources and lacking product identifiers.

    High risk
  15. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.

    High risk
  16. The Albertsons Companies Incorporated

    FDA warns Albertsons that recalled ByHeart infant formula tied to 51 infant botulism cases stayed on its store shelves for days.

    High risk
  17. Catalent Indiana, LLC

    Catalent Indiana's Bloomington plant released sterile vials contaminated with mammalian hair and failed to investigate, FDA says.

    High risk
  18. DeVere Manufacturing Inc.

    FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.

    High risk
  19. DermaRite Industries, LLC

    DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.

    High risk
  20. Uriel Pharmacy, Inc.

    Uriel Pharmacy's homeopathic ampule drugs are unapproved new drugs and were made under serious CGMP violations.

    High risk
  21. Apotex Inc.

    FDA cited Apotex's Richmond Hill sterile plant for failed investigations and aseptic contamination risks, prompting recalls.

    High risk
  22. Kath Khemicals LLC

    FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.

    High risk
  23. Kabana Skin Care LLC

    Kabana Skin Care failed to test OTC drug ingredients and finished products, prompting a recall and halt of U.S. drug manufacturing.

    High risk
  24. Macsen Drugs

    FDA cites Macsen Drugs for releasing fire-exposed APIs and inadequate stability data at India plant.

    High risk
  25. Medical Chemical Corporation

    FDA warned Medical Chemical Corp over manufacturing violations, unapproved Tincture Green Soap, and improper drug listing.

    High risk
  26. Jack & The Green Sprouts, Inc.

    FDA warns Jack & The Green Sprouts after sprout samples tested positive for Listeria and inspection found insanitary conditions.

    High risk
  27. Excelvision Fareva

    Excelvision Fareva, a sterile drug manufacturer, was cited for inadequate mold/black-speck complaint investigations and aseptic contamination controls.

    High risk
  28. Randox Laboratories Limited

    FDA warned Randox Laboratories over inadequate risk analysis and corrective actions for carryover errors in RX series analyzers.

    High risk
  29. Brands International Corporation

    Brands International, a Canadian drug manufacturer, limited an FDA inspection and had manufacturing quality violations including mold contamination.

    High risk
  30. Micro Orgo Chem

    Micro Orgo Chem in India failed CGMP for API drugs, including cleaning, process validation, stability and records.

    High risk
  31. Becton, Dickinson, and Company/CareFusion 303, Inc.

    FDA warned Becton Dickinson/CareFusion over Pyxis medication dispensing systems with unresolved software defects, missed MDR reports and unreported recalls.

    High risk
  32. Mid America Pet Food LLC

    FDA warned Mid America Pet Food after Salmonella-linked recalls and found persistent contamination and animal-food safety-rule violations at its Texas plant.

    High risk
  33. Makra Kozmetika D.O.O.

    FDA warns Makra Kozmetika over OTC drug manufacturing violations, including missing batch and ingredient testing, after April 2024 inspection.

    High risk
  34. Aerosol and Liquid Packaging, Inc.

    FDA warns Aerosol and Liquid Packaging on CGMP failures and unapproved antiseptic spray claims.

    High risk
  35. Zydus Lifesciences Limited

    FDA warned Zydus Lifesciences over cross-contamination and glass particles in its injectable drugs, leading to recalls.

    High risk
  36. AnuMed International, LLC

    FDA warned AnuMed International about unapproved drugs, misleading FDA claims, and manufacturing quality failures.

    High risk
  37. Central Admixture Pharmacy Services, Inc.

    FDA warns Central Admixture Pharmacy Services over sterile compounded drugs, contamination risks, and quality failures at its San Diego site.

    High risk
  38. ARG Laboratories, Inc.

    FDA found ARG Laboratories released failing over-the-counter drug lots, lacked manufacturing controls, and marketed two unapproved pain creams.

    High risk
  39. Art of Beauty Company, Inc.

    FDA warned Art of Beauty over manufacturing-rule violations in OTC hand sanitizer, including missing component and finished-product testing.

    High risk
  40. Laboratorio Magnachem International

    FDA cited Laboratorio Magnachem for CGMP failures and unapproved, misbranded Broncochem cough/cold drugs after a 2023 inspection.

    High risk
  41. PepsiCo, Inc.

    FDA warned PepsiCo after Salmonella Cubana was found at its Danville, Illinois Quaker Oats plant, prompting recalls of granola bars and cereals.

    High risk
  42. Chang and Son Enterprises, Inc.

    FDA found Listeria monocytogenes in Chang and Son's mung bean and soybean sprout operation and in its sprouts.

    High risk
  43. Aruba Aloe Balm N.V.

    Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.

    High risk
  44. Central Admixture Pharmacy Services, Inc.

    FDA warned sterile drug compounder Central Admixture Pharmacy Services (Phoenix) that dirty areas and weak sterility testing made its drugs adulterated.

    High risk
  45. Litehouse, Inc.

    Litehouse recalled Simple Truth Plant Based Ranch Dressing after mislabeled containers led to undeclared soy from Caesar Dressing.

    High risk
  46. Cardinal Health

    Cardinal Health marketed convenience kits with unapproved syringes and lacked supplier qualification for infusion-pump-compatible Monoject syringes.

    High risk
  47. Lipari Foods Operating Company, LLC

    Lipari Foods subsidiary JLM Manufacturing recalled walnut, hazelnut, and cashew products because labels did not declare major allergens.

    High risk
  48. Fresenius Kabi AG

    FDA warned Fresenius Kabi about quality and reporting failures for its Ivenix Infusion System.

    High risk
  49. Gilster-Mary Lee Corporation

    Gilster-Mary Lee's recalled HyVee skillet meal was misbranded because its label did not declare milk, a major allergen.

    High risk
  50. Battle Creek Co-op/CHS, LLC dba Progressive Nutrition

    Progressive Nutrition's cattle feed contained excess urea linked to 17 cattle deaths, with preventive-control and medicated-feed violations.

    High risk